Phase 1 Study of JNJ-212082 (Abiraterone Acetate) in Patients With Castration-Resistant Prostate Cancer.
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2015
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisolone
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Janssen Pharmaceutical KK
- 07 Jun 2017 Biomarkers information updated
- 02 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Sep 2012 Planned End Date changed from 1 Feb 2015 to 1 Sep 2014 as reported by ClinicalTrials.gov.